Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls Sells 54,702 Shares

Savara Inc (NASDAQ:SVRA) CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Savara Stock Up 1.6 %

Shares of SVRA traded up $0.05 during trading hours on Monday, reaching $3.26. The company’s stock had a trading volume of 846,141 shares, compared to its average volume of 1,276,285. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm has a market cap of $559.48 million, a price-to-earnings ratio of -7.47 and a beta of 0.92. The company has a 50 day moving average of $3.52 and a two-hundred day moving average of $4.02. Savara Inc has a 1-year low of $2.82 and a 1-year high of $5.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). As a group, research analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. HC Wainwright reduced their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Evercore ISI restated an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.17.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its stake in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of Savara by 90.5% in the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock valued at $18,377,000 after buying an additional 2,165,701 shares in the last quarter. First Light Asset Management LLC acquired a new position in Savara in the second quarter worth approximately $8,069,000. Finally, Wellington Management Group LLP raised its position in Savara by 22.9% during the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.